Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
US Stock Futures Surge Ahead Of Fed Meeting
Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal (Investor's Business Daily)
Related SNY
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
US Stock Futures Surge Ahead Of Fed Meeting
Pfizer, Merck Beat Q2 Views; Sanofi Makes PD-1 Deal (Investor's Business Daily)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

Get Benzinga's Newsletters